# PAF Kapital

> PAF Kapital is a VC fund backing Medical, Medical Device and Pharmaceutical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 1
- Last investment: Apr 2020
- Lead investor: 0%
- Last updated: Aug 2026

PAF Kapital is a investment structure in young companies in the health sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Medical Device | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dianosic | Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $1.6M | Seed | Apr 14, 2020 |  |

1 of 1 investments shown.

## Co-investors
- [Banque Populaire Rives de Paris](https://shizune.co/investors/profile/banque-populaire-rives-de-paris) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Caisse d’Epargne](https://shizune.co/investors/profile/caisse-d-epargne) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does PAF Kapital invest in?

PAF Kapital invests primarily in Medical, Medical Device and Pharmaceutical startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did PAF Kapital last invest?

The most recent investment recorded for PAF Kapital closed in Apr 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co